(Q34397840)

1 August 2017

1 reference

title

United States Cholesterol Guidelines 2001: expanded scope of intensive low-density lipoprotein-lowering therapy (English)

1 reference

1 August 2017

main subject

United States of America

0 references

1 reference

Grundy SM

1

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

American Journal of Cardiology

1 August 2017

published in

1 reference

1 August 2017

volume

88

1 reference

1 August 2017

issue

7B

1 reference

1 August 2017

page(s)

23J-27J

1 reference

Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901931-2

The value of lowering cholesterol after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901931-2

Clinical goals and performance measures for cholesterol management in secondary prevention of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901931-2

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901931-2

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901931-2

Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901931-2

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901931-2

Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901931-2

Interrelationships among insulin's antilipolytic and glucoregulatory effects and plasma triglycerides in nondiabetic and diabetic patients with endogenous hypertriglyceridemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901931-2

By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901931-2

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901931-2

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901931-2

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901931-2

10.1016/S0002-9149(01)01931-2

7 January 2021

Identifiers

DOI

1 reference

1 August 2017

1 reference